David Davenport
Director, US Policy Alliance for Regenerative Medicine
As Director, U.S. Policy at the Alliance for Regenerative Medicine (ARM), David collaborates with ARM’s internal and external stakeholders to develop, drive, and execute ARM’s strategy for advancing its U.S. policy objectives at the federal level, with a focus on access and reimbursement issues impacting cell and gene therapy. He brings a decade of policy and government affairs expertise, with a track record of influencing policymakers and driving consensus across diverse stakeholders to improve the health care patients receive.
Seminars
Thursday 16th July 2026
Streamlining Out-of-State Medicaid Provider Credentialing to Accelerate Cell & Gene Therapy Access
3:00 pm
- Highlighting how fragmented state credentialing rules create delays for patients receiving care out-of-state
- Outlining practical, scalable recommendations to streamline Medicaid provider credentialing for children and adults who need timely access to specialist‑delivered therapies
- Next steps for implementing the Accelerating Kids Access to Care Act, recently passed by Congress
